Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for the treatment of iron deficiency anemia in patients with inflammatory bowel disease in Spain.

Federico Argüelles-AriasFernando BermejoJoaquín Borrás-BlascoEugeni DomènechBeatriz SiciliaJosé M HuguetAntonio Ramirez de ArellanoWilliam J ValentineBarnaby Hunt

Published in: Therapeutic advances in gastroenterology (2022)

The present analysis suggests that FCM is less costly and more effective than IS for the treatment of IDA subsequent to IBD in Spain and therefore was considered dominant.

Keyphrases

iron deficiency
patients with inflammatory bowel disease
chronic kidney disease
replacement therapy
smoking cessation
ulcerative colitis